An antitumor response was observed in phase 1 clinical trial, NCT02541370, that recruited 23 patients suffering from HCC (n = 14), PC (n = 7), and CRC (n = 2), treated with CD133 CAR-T cells [245]. The gene discussed is PROM1; the disease is hepatocellular carcinoma.